Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1860657 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.16Day −1.69%Mkt cap $18M1Y +9.4%Off 52W high −50.6%Vol (1Y) 96.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,148 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.9% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.15% |
| Top-10 13F concentration99.2% |
| Next report (est.)2026-10-08 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$320,000 |
| Earnings (TTM)-$11.2M |
| ROE−103.8% |
| Net margin−3509.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+7.4% |
| 1Y+9.4% |
| 3Y−99.9% |
| Since incept. (ann.)−96.9% |
Total return through 2026-07-29 · series begins 2021-12-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)96.7% |
| Ann. volatility (3Y)103.0% |
| Sharpe (1Y)0.48 |
| Sharpe (3Y)−1.83 |
| Max drawdown (1Y)−58.9% |
| Max drawdown (3Y)−100.0% |
| Beta (3Y vs SPY)1.36 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 228,084 | $248,612 | 1.44% | −7.9% |
| GEODE CAPITAL MANAGEMENT, LLC | 190,393 | $207,528 | 1.20% | +21.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 171,795 | $187,257 | 1.09% | new |
| STATE STREET CORP | 137,600 | $149,984 | 0.87% | +0.0% |
| VANGUARD FIDUCIARY TRUST CO | 74,913 | $81,655 | 0.47% | new |
| NORTHERN TRUST CORP | 48,103 | $52,432 | 0.30% | +66.2% |
| XTX Topco Ltd | 28,967 | $31,574 | 0.18% | −13.9% |
| TWO SIGMA INVESTMENTS, LP | 27,492 | $29,966 | 0.17% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-01 | — | — | $25,000 | — |
| 2025-03-31 | 2025-05-09 | — | — | $0 | — |
| 2024-06-30 | 2024-08-05 | — | — | — | — |
| 2024-03-31 | 2024-05-14 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-08 is ESTIMATED from filing cadence (median gap 95d) — not company-confirmed.
License 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
